Safety and Effectiveness of BPaL-Based Regimens to Treat Multidrug-Resistant TB: First Experience of an Italian Tuberculosis Referral Hospital
<b>Background/Objectives</b>: Tuberculosis (TB) is preventable and curable, but multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) pose significant challenges worldwide due to the limited treatment options, lengths of therapies, and high rates of treatment failure...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-12-01
|
| Series: | Antibiotics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2079-6382/14/1/7 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832589337792872448 |
|---|---|
| author | Gina Gualano Maria Musso Paola Mencarini Silvia Mosti Carlotta Cerva Pietro Vittozzi Antonio Mazzarelli Angela Cannas Assunta Navarra Stefania Ianniello Paolo Faccendini Fabrizio Palmieri |
| author_facet | Gina Gualano Maria Musso Paola Mencarini Silvia Mosti Carlotta Cerva Pietro Vittozzi Antonio Mazzarelli Angela Cannas Assunta Navarra Stefania Ianniello Paolo Faccendini Fabrizio Palmieri |
| author_sort | Gina Gualano |
| collection | DOAJ |
| description | <b>Background/Objectives</b>: Tuberculosis (TB) is preventable and curable, but multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) pose significant challenges worldwide due to the limited treatment options, lengths of therapies, and high rates of treatment failure. The management of MDR-TB has been revolutionized by all oral anti-TB drug regimens that are likely to improve adherence and treatment outcomes. These regimes include bedaquiline (B), pretomanid (P), and linezolid (L) (BPaL), and moxifloxacin if resistance to fluoroquinolones is not detected (BPaLM). Based on the evidence generated by the TB-PRACTECAL and ZeNix randomized controlled trials, BPaL/BPaLM regimens are recommended over the currently recommended longer regimens in patients with MDR-TB or monoresistance to rifampin (RR). To our knowledge, no data are currently available on the implementation of BPaL/BPaLM regimens in Italy. <b>Results</b>: Seventeen patients completed the BPaL/BPaLM regimen, with a treatment success rate of 90% (17/19), consistent with the literature data. Eleven patients out of the nineteen retained in care (58%) complained about symptoms consistent with adverse events (AEs). No treatment interruption was necessary due to AEs. <b>Methods</b>: Here, we report the real-world experience of a tertiary referral hospital for TB in Italy, from 2022 to 2024, in the management, outcomes, and adverse drug reactions of a cohort of twenty-two MDR/RR patients treated with BPaL and BPaLM regimens. <b>Conclusions</b>: BPaL-containing regimens also serve as promising options for patients with RR/MDR-TB in terms of real-life experience, but further multicentric studies are required in Europe to confirm the efficacy of shorter regimens to eliminate MDR TB. |
| format | Article |
| id | doaj-art-8204ef31bc074abdaee71d72266075be |
| institution | Kabale University |
| issn | 2079-6382 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Antibiotics |
| spelling | doaj-art-8204ef31bc074abdaee71d72266075be2025-01-24T13:18:29ZengMDPI AGAntibiotics2079-63822024-12-01141710.3390/antibiotics14010007Safety and Effectiveness of BPaL-Based Regimens to Treat Multidrug-Resistant TB: First Experience of an Italian Tuberculosis Referral HospitalGina Gualano0Maria Musso1Paola Mencarini2Silvia Mosti3Carlotta Cerva4Pietro Vittozzi5Antonio Mazzarelli6Angela Cannas7Assunta Navarra8Stefania Ianniello9Paolo Faccendini10Fabrizio Palmieri11Respiratory Infectious Diseases Unit, National Institute for Infectious Diseases “Lazzaro Spallanzani” IRCCS, 00149 Rome, ItalyRespiratory Infectious Diseases Unit, National Institute for Infectious Diseases “Lazzaro Spallanzani” IRCCS, 00149 Rome, ItalyRespiratory Infectious Diseases Unit, National Institute for Infectious Diseases “Lazzaro Spallanzani” IRCCS, 00149 Rome, ItalyRespiratory Infectious Diseases Unit, National Institute for Infectious Diseases “Lazzaro Spallanzani” IRCCS, 00149 Rome, ItalyRespiratory Infectious Diseases Unit, National Institute for Infectious Diseases “Lazzaro Spallanzani” IRCCS, 00149 Rome, ItalyRespiratory Infectious Diseases Unit, National Institute for Infectious Diseases “Lazzaro Spallanzani” IRCCS, 00149 Rome, ItalyDepartment of Microbiology, National Institute for Infectious Diseases “Lazzaro Spallanzani” IRCCS, 00149 Rome, ItalyDepartment of Microbiology, National Institute for Infectious Diseases “Lazzaro Spallanzani” IRCCS, 00149 Rome, ItalyDepartment of Epidemiology, National Institute for Infectious Diseases “Lazzaro Spallanzani” IRCCS, 00149 Rome, ItalyDiagnostic Imaging Unit for Infectious Diseases, National Institute for Infectious Diseases “Lazzaro Spallanzani” IRCCS, 00149 Rome, ItalyHospital Pharmacy, National Institute for Infectious Diseases “Lazzaro Spallanzani” IRCCS, 00149 Rome, ItalyRespiratory Infectious Diseases Unit, National Institute for Infectious Diseases “Lazzaro Spallanzani” IRCCS, 00149 Rome, Italy<b>Background/Objectives</b>: Tuberculosis (TB) is preventable and curable, but multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) pose significant challenges worldwide due to the limited treatment options, lengths of therapies, and high rates of treatment failure. The management of MDR-TB has been revolutionized by all oral anti-TB drug regimens that are likely to improve adherence and treatment outcomes. These regimes include bedaquiline (B), pretomanid (P), and linezolid (L) (BPaL), and moxifloxacin if resistance to fluoroquinolones is not detected (BPaLM). Based on the evidence generated by the TB-PRACTECAL and ZeNix randomized controlled trials, BPaL/BPaLM regimens are recommended over the currently recommended longer regimens in patients with MDR-TB or monoresistance to rifampin (RR). To our knowledge, no data are currently available on the implementation of BPaL/BPaLM regimens in Italy. <b>Results</b>: Seventeen patients completed the BPaL/BPaLM regimen, with a treatment success rate of 90% (17/19), consistent with the literature data. Eleven patients out of the nineteen retained in care (58%) complained about symptoms consistent with adverse events (AEs). No treatment interruption was necessary due to AEs. <b>Methods</b>: Here, we report the real-world experience of a tertiary referral hospital for TB in Italy, from 2022 to 2024, in the management, outcomes, and adverse drug reactions of a cohort of twenty-two MDR/RR patients treated with BPaL and BPaLM regimens. <b>Conclusions</b>: BPaL-containing regimens also serve as promising options for patients with RR/MDR-TB in terms of real-life experience, but further multicentric studies are required in Europe to confirm the efficacy of shorter regimens to eliminate MDR TB.https://www.mdpi.com/2079-6382/14/1/7multidrug-resistant TBBPaL regimensItaly |
| spellingShingle | Gina Gualano Maria Musso Paola Mencarini Silvia Mosti Carlotta Cerva Pietro Vittozzi Antonio Mazzarelli Angela Cannas Assunta Navarra Stefania Ianniello Paolo Faccendini Fabrizio Palmieri Safety and Effectiveness of BPaL-Based Regimens to Treat Multidrug-Resistant TB: First Experience of an Italian Tuberculosis Referral Hospital Antibiotics multidrug-resistant TB BPaL regimens Italy |
| title | Safety and Effectiveness of BPaL-Based Regimens to Treat Multidrug-Resistant TB: First Experience of an Italian Tuberculosis Referral Hospital |
| title_full | Safety and Effectiveness of BPaL-Based Regimens to Treat Multidrug-Resistant TB: First Experience of an Italian Tuberculosis Referral Hospital |
| title_fullStr | Safety and Effectiveness of BPaL-Based Regimens to Treat Multidrug-Resistant TB: First Experience of an Italian Tuberculosis Referral Hospital |
| title_full_unstemmed | Safety and Effectiveness of BPaL-Based Regimens to Treat Multidrug-Resistant TB: First Experience of an Italian Tuberculosis Referral Hospital |
| title_short | Safety and Effectiveness of BPaL-Based Regimens to Treat Multidrug-Resistant TB: First Experience of an Italian Tuberculosis Referral Hospital |
| title_sort | safety and effectiveness of bpal based regimens to treat multidrug resistant tb first experience of an italian tuberculosis referral hospital |
| topic | multidrug-resistant TB BPaL regimens Italy |
| url | https://www.mdpi.com/2079-6382/14/1/7 |
| work_keys_str_mv | AT ginagualano safetyandeffectivenessofbpalbasedregimenstotreatmultidrugresistanttbfirstexperienceofanitaliantuberculosisreferralhospital AT mariamusso safetyandeffectivenessofbpalbasedregimenstotreatmultidrugresistanttbfirstexperienceofanitaliantuberculosisreferralhospital AT paolamencarini safetyandeffectivenessofbpalbasedregimenstotreatmultidrugresistanttbfirstexperienceofanitaliantuberculosisreferralhospital AT silviamosti safetyandeffectivenessofbpalbasedregimenstotreatmultidrugresistanttbfirstexperienceofanitaliantuberculosisreferralhospital AT carlottacerva safetyandeffectivenessofbpalbasedregimenstotreatmultidrugresistanttbfirstexperienceofanitaliantuberculosisreferralhospital AT pietrovittozzi safetyandeffectivenessofbpalbasedregimenstotreatmultidrugresistanttbfirstexperienceofanitaliantuberculosisreferralhospital AT antoniomazzarelli safetyandeffectivenessofbpalbasedregimenstotreatmultidrugresistanttbfirstexperienceofanitaliantuberculosisreferralhospital AT angelacannas safetyandeffectivenessofbpalbasedregimenstotreatmultidrugresistanttbfirstexperienceofanitaliantuberculosisreferralhospital AT assuntanavarra safetyandeffectivenessofbpalbasedregimenstotreatmultidrugresistanttbfirstexperienceofanitaliantuberculosisreferralhospital AT stefaniaianniello safetyandeffectivenessofbpalbasedregimenstotreatmultidrugresistanttbfirstexperienceofanitaliantuberculosisreferralhospital AT paolofaccendini safetyandeffectivenessofbpalbasedregimenstotreatmultidrugresistanttbfirstexperienceofanitaliantuberculosisreferralhospital AT fabriziopalmieri safetyandeffectivenessofbpalbasedregimenstotreatmultidrugresistanttbfirstexperienceofanitaliantuberculosisreferralhospital |